Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
CN |
|
Accrol Group Holdings PLC
LSE:ACRL
|
UK |
|
S
|
Shanxi Lanhua Sci-Tech Venture Co Ltd
SSE:600123
|
CN |
|
J
|
Jay Mart PCL
SET:JMART
|
TH |
|
Boostheat SAS
PAR:ALBOO
|
FR |
Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 108 full-time employees. The company went IPO on 2021-03-19. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. The company is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The firm mainly conducts its businesses in the China market.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
